| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Rituximab-based regimens for primary cardiac lymphoma: A systematic review of outcomes, challenges and future directions
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Syed Faqeer Hussain Bokhari, Danyal Bakht, Abdul Haseeb Hasan, Muhammad Ali Abid, Maaz Amir, Khawar Ali, Muhammad Arsham Javed, Faria Khilji, Asma Iqbal and Wahidullah Dost |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wahidullah Dost, Curative medicine, Kabul University of Medical Sciences, Karte-e-sakhi Kabul, Kabul 10001, Kābul, Afghanistan. wahidullahdost96@gmail.com |
| Key Words |
Primary cardiac lymphoma; Oncology; Review; Rituximab; B cell lymphoma |
| Core Tip |
This systematic review highlights the efficacy of rituximab-based regimens, particularly rituximab, cyclophosphamide, doxorubicin, oncovin, and prednisolone, in managing primary cardiac lymphoma, a rare and aggressive malignancy. Diffuse large B-cell lymphoma is the most common subtype, and combination therapies, including surgical intervention, show promise in achieving complete remission. However, variability in treatment responses and the risk of adverse events remain significant challenges. Enhanced diagnostic methods and further research are essential to optimize therapeutic strategies and improve outcomes for patients with this rare cardiac tumor. |
| Publish Date |
2025-05-20 03:37 |
| Citation |
<p>Bokhari SFH, Bakht D, Hasan AH, Abid MA, Amir M, Ali K, Javed MA, Khilji F, Iqbal A, Dost W. Rituximab-based regimens for primary cardiac lymphoma: A systematic review of outcomes, challenges and future directions. <i>World J Clin Oncol</i> 2025; 16(5): 104471</p> |
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i5/104471.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i5.104471 |
